Section Arrow
URGN.NASDAQ
- UroGen Pharma Ltd
Quotes are at least 15-min delayed:2024/12/24 13:19 EST
Last
 10.82
+0.11 (+1.03%)
Day High 
10.88 
Prev. Close
10.71 
1-M High
13.1332 
Volume 
228.81K 
Bid
10.82
Ask
11
Day Low
10.5066 
Open
10.65 
1-M Low
10.26 
Market Cap 
451.96M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.18 
20-SMA 11.82 
50-SMA 12.01 
52-W High 20.7 
52-W Low 10.26 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.02/-3.74
Enterprise Value
551.35M
Balance Sheet
Book Value Per Share
0.60
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
82.71M
Operating Revenue Per Share
1.72
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed:2024/12/24 13:19 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.